Durvalumab after chemoradiotherapy in non-small cell lung cancer harboring driver gene mutation/translocation: a retrospective multicenter study (HOT2101)

Durvalumab after chemoradiotherapy in non-small cell lung cancer harboring driver gene mutation/translocation: a retrospective multicenter study (HOT2101) - HOT2101

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048100

Enrollment

Registered

2022-06-20

Start date

2021-12-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically- or cytologically-confirmed NSCLC with driver gene positive defined as EGFR, ALK, ROS1, BRAF, NTRK, MET, RET, and KRAS by December 31, 2021. 2. Patients with locally advanced or postoperative recurrent, unresectable NSCLC. 3. Patients who do not refuse to participate in this study.

Exclusion criteria

Exclusion criteria: Patients who were deemed inappropriate for enrollment by investigators

Design outcomes

Primary

Measure	Time frame
To provide insights into outcomes of durvalumab consolidation efficacy and safety in non-small cell lung cancer harboring driver gene mutation/translocation.	—

Secondary

Measure	Time frame
1. progression free survival 2. overall survival	—

Countries

Japan

Contacts

Public ContactKosuke Tsuji

Hokkaido University Graduate School of Medicine Department of Respiratory Medicine

kosuke_ko17@pop.med.hokudai.ac.jp011-706-5911

Outcome results